The Nutrigenomic Landscape of Mitochondrial Metabolism: Targeting Growth Factor Signaling in Translational Oncology

Background: The metabolic flexibility of cancer cells, primarily driven by mitochondrial reprogramming and constitutive Growth Factor Signaling (GFS), remains a formidable barrier to therapeutic success. While the “Warburg Effect” was traditionally viewed as a consequence of irreversible mitochondrial defects, modern evidence suggests a proactive “metabolic hijacking” where growth factors drive mitochondrial plasticity to support rapid biomass accumulation. Aim: This review aims to synthesize the molecular cross-talk between dietary bioactives and the mitochondrial-GFS axis, proposing a “Triple-Hit” framework to overcome drug resistance. Main Body: the PI3K/Akt/mTOR and IGF-1 axes as master regulators of glycolytic commitment is dissected. mitochondrial dynamics, detailing how bioactives like Quercetin and EGCG modulate fission/fusion protein ratios (Drp1/Mfn2) to restore apoptotic sensitivity are explored. Furthermore, “Mito-Epigenetics,” examining growth factor-mediated hypermethylation of the mitochondrial D-loop and its reversal via nutrigenomic HDAC and DNMT inhibitors are analyzed. Conclusion: It is concluded that the future of oncology lies in “Nutri-phenotyping”—transitioning from generic dietary advice to molecularly-targeted nutrition. This integration is essential for closing the “translational gap” and improving patient outcomes in the era of precision medicine.